Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Perrigo (PRGO)

Perrigo completes sale of Dermacosmetics business to Karo for €305.6 million upfront

Neutral Impact 3 of 5 m&a Written later

Perrigo completed the sale of its Dermacosmetics branded business to Karo Healthcare on April 30, 2026. Karo paid €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, with up to €27.0 million more contingent on net sales milestones over three years. The company says the net proceeds will be used primarily to reduce debt.

Key points

  • Closed April 30, 2026, with upfront cash of €305.6 million, including €5.6 million in net working capital adjustments
  • Up to €27.0 million in additional contingent consideration, tied to net sales milestones over three years
  • Net proceeds expected to be used primarily to reduce debt, according to CEO Patrick Lockwood-Taylor
  • Business generated about €120 million in net sales in calendar 2025, or about 5% of adjusted operating income

The filing

CompanyPerrigo (PRGO)
Form8-K, current report
Filed with the SECApr 30, 2026, 4:43 PM ET
Accession number0001585364-26-000040

Items reported: 2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.